This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Drugs

Safety Worries Over Celgene's Experimental Crohn's Drug Overblown

Safety Worries Over Celgene's Experimental Crohn's Drug Overblown

  • Tickers in this article:
  • CELG

The first public presentation of the GED-031 phase II data will be on Oct. 21 at a European medical conference.

09/17/14 - 08:26 AM EDT

September 17 Premarket Briefing: 10 Things You Should Know

U.S. stock futures are mixed; a rates announcement from the Federal Reserve is expected Wednesday afternoon; Trian launches campaign to break up DuPont; Endo makes bid for Auxilium.

09/17/14 - 06:56 AM EDT

Try Jim Cramer's Action Alerts PLUS
Why It's Time for Allergan Shareholders to Take Some Profits

Why It's Time for Allergan Shareholders to Take Some Profits

The current dividend does not pay enough for investors to stay.

09/16/14 - 01:09 PM EDT

Doc Offers Glimpse Into Arena Pharma Weight-Loss Combination Therapy

Doc Offers Glimpse Into Arena Pharma Weight-Loss Combination Therapy

Patients lost 12% of their body weight following 12 weeks of treatment with Arena's Belviq plus phentermine.

09/16/14 - 09:48 AM EDT

Gilead Expands Access of Hepatitis C Drug in Developing Countries

  • Tickers in this article:
  • GILD
  • MYL

Gilead said it will license its hepatitis C drug Sovaldi to seven drugmakers in India to expand access to the medicine in developing countries.

09/15/14 - 01:38 PM EDT

NPS Pharma Hormone Drug Wins Shaky Endorsement From FDA Panel

NPS Pharma Hormone Drug Wins Shaky Endorsement From FDA Panel

  • Tickers in this article:
  • NPSP

NPS Pharmaceuticals shares are weak Monday following a rough outing for its hormone replacement therapy Natpara at an FDA advisory panel on Friday.

09/15/14 - 09:32 AM EDT

Ebola-Stricken Doc Receives Experimental Drug, But Which One?

Ebola-Stricken Doc Receives Experimental Drug, But Which One?

Twitter abuzz with speculation that Tekmira's experimental Ebola therapy is being used to treat patient.

09/11/14 - 02:20 PM EDT

Trade Ebola Stocks? Sure, But Don't Bet on Big Business Opportunity

Trade Ebola Stocks? Sure, But Don't Bet on Big Business Opportunity

The Ebola outbreak in West Africa is a public health emergency which has also captured the attention of U.S. investors (perhaps I should say traders.)

09/10/14 - 09:36 AM EDT

Retrophin Assailed for 'Exorbitant' Price Hike

Retrophin Assailed for 'Exorbitant' Price Hike

  • Tickers in this article:
  • RTRX

Doctor asks when profit becomes profiteering after Retrophin raises drug price by 20 times.

09/10/14 - 08:28 AM EDT

Why the Tax 'Inversion' Controversy Doesn't Matter

Why the Tax 'Inversion' Controversy Doesn't Matter

Of all the things Congress and President Obama might do to hurt the stock market, closing tax loopholes on corporate tax 'inversion' mergers isn't one of them.

09/09/14 - 01:47 PM EDT

Two Promising Gene Therapy Stocks Tackling Eye Disease

Two Promising Gene Therapy Stocks Tackling Eye Disease

Investors will get a first look at data from an early stage study of an Applied Genetic therapy on Friday.

09/09/14 - 09:04 AM EDT

Biotech Stock Mailbag: Achillion, Ariad Revisited, Endocyte

Biotech Stock Mailbag: Achillion, Ariad Revisited, Endocyte

Biotech columnist Adam Feuerstein answers readers' questions about health care.

09/05/14 - 08:55 AM EDT

Novartis Offers Healthy Gains at a Bargain Stock Price

Novartis Offers Healthy Gains at a Bargain Stock Price

The company has a potential life-saving catalyst in its portfolio, too.

09/05/14 - 06:30 AM EDT

Merck Skin Cancer Immunotherapy Gets FDA Approval

Merck Skin Cancer Immunotherapy Gets FDA Approval

  • Tickers in this article:
  • MRK

Merck will sell the skin cancer drug under the brand name Keytruda.

09/04/14 - 02:36 PM EDT

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
DOW 17,265.99 +109.14 0.64%
S&P 500 2,011.36 +9.79 0.49%
NASDAQ 4,593.4250 +31.2360 0.68%

Brokerage Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs